Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study DOI
Heather E. Webber,

Jessica C. Badawi,

Douglas Calvillo

et al.

Journal of Addictive Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 8

Published: Dec. 28, 2024

Background: No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved insomnia treatment, reduces MA self-administration and MA-induced reinstatement responding in preclinical studies. SUVO may also reduce by targeting substance risk factors, including insomnia, stress, cue reactivity, craving. This case series study assessed the (1) feasibility safety of administering suvorexant sample individuals with MUD; (2) preliminary effects on objective subjective measures sleep, reactivity/craving. Method: Participants (n = 3) were randomized to receive 1 week or placebo using within-subject, crossover design 1-week washout period between doses. completed self-report (sleep quality, stress), behavioral (cold pressor task), physiological (heart rate, electroencephalogram) during all three weeks. wore Fitbit monitor sleep throughout study. Results: visits tasks. One report severe drowsiness headache made; no other side associated SUVO. improved total time resulted lower resting-state alpha power, but was mixed quality. administration increased overall brain reactivity cues not specific reduced though self-reported stress demonstrated results. Conclusion: safe tolerable MUD sample. Future research benefit from investigating well-controlled larger

Language: Английский

Emerging strategies and clinical recommendations for the management of novel depression subtypes DOI Creative Commons
Stefania Chiappini, Gaia Sampogna,

Antonio Ventriglio

et al.

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21

Published: Feb. 27, 2025

Introduction The phenomenology of depression is characterized by a wide array emotional, cognitive, and physical symptoms that significantly disrupt an individual's life. Societal changes, driven technological advancements, economic pressures, environmental concerns including climate change, shifting cultural norms, have influenced how manifests understood. These developments led to the identification new subtypes, highlighting need for personalized treatment approaches based on individual underlying causes.

Language: Английский

Citations

2
Advancing Research Translation in Addiction and Pain: A Portfolio Analysis of the NIH HEAL Initiative DOI Creative Commons
Ginnie Sawyer-Morris,

Merve Ulukaya,

Bryce Kushmerick-McCune

et al.

Journal of Clinical and Translational Science, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 49

Published: April 14, 2025

To date, the NIH Helping to End Addiction Long-term (HEAL) Initiative has funded over 1,000 projects that aim identify new therapeutic targets for pain and substance use disorder (SUD), develop nonpharmacological strategies management, improve overdose addiction treatment across settings. This study conducted a portfolio analysis of HEAL's research assess opportunities advance translation implementation. HEAL (FY 2018-2022) were classified into early (T0-T1) later (T2-T4) translational stages. Eleven coders used 54-item data collection tool based on Consolidated Framework Implementation Research (CFIR) extract project characteristics (e.g., population, setting) relevant Descriptive statistics visualization techniques employed analyze map aggregate onto CFIR's domains outer setting). comprised 923 (33.7% T0-T1; 67.3% T2-T4), ranging from basic science (27.1%) preclinical (21.4%) clinical (36.8%), implementation (27.1%), dissemination (13.1%). Most primarily addressed either (46.3%) or (37.4%). Implementation-related gaps included underrepresentation certain populations sexual/gender minorities: 0.5%). T0-T1 occurred in laboratory settings (35.1%), while T2-T4 concentrated healthcare hospitals: 21.6%) with limited transferability other contexts community: 12.9%). Opportunities efforts include fostering interdisciplinary collaboration, prioritizing underserved populations, engaging community leaders policy stakeholders, targeting evidence-based practices nonclinical Ongoing analyses can guide strategic investments maximize impact crises.

Language: Английский

Citations

2
Novel therapeutics in development for the treatment of stimulant-use disorder DOI Creative Commons

Erica J. Young,

László Radnai,

В. А. Приходько

et al.

Current Opinion in Neurobiology, Journal Year: 2024, Volume and Issue: 87, P. 102898 - 102898

Published: Aug. 1, 2024

Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, prescription such as methylphenidate. Unlike opioids alcohol, there no therapies approved by the US Food Drug Administration (FDA) treat stimulant-use disorder. The high rate of relapse among this population highlights insufficiency current treatment options, which limited abstinence support programs behavioral modification therapies. Here, we briefly outline recent regulatory actions taken FDA help development new stimulant use disorder treatments highlight several therapeutics in clinical pipeline.

Language: Английский

Citations

3
Art therapy’s engagement of brain networks for enduring recovery from addiction DOI Creative Commons

Patricia O. Quinn

Frontiers in Psychiatry, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 6, 2025

The field of addiction in its priority to save lives has emphasized harm reduction and medication therapies that have taken precedence over counseling psychotherapy. extensive mental health needs, traumatic histories cognitive challenges this population call for more availability all treatments, but also in-depth treatment the causes addiction. prevalence trauma is examined with regard challenge it presents substance use disorder (SUD), other comorbidities. Two case examples are offered exemplify how art therapy expedites key information about underlying trauma. Art proposed as a approach SUD apparent activation neural networks impacted by trauma, usefulness engaging those who experientially. Quantitative research cited suggests therapy's reward system, which may make useful treating stress inhibition coefficients map need additional empirical improve efficiency effectiveness treatment.

Language: Английский

Citations

0
Stimulant-Involved Cardiovascular Disease Mortality and Life Years Lost, 2014 to 2023 DOI
Rebecca Arden Harris, Sameed Ahmed M. Khatana, Dana A. Glei

et al.

Substance Use Research and Treatment, Journal Year: 2025, Volume and Issue: 19

Published: May 1, 2025

Background: Cocaine and methamphetamine, highly cardiotoxic stimulants, are associated with increased risks of hypertension, coronary artery disease, arrhythmias, cardiomyopathy, stroke. Objectives: This study examines trends in stimulant-involved cardiovascular disease (CVD) mortality the U.S. from 2014 to 2023, analyzing CVD subtypes, stimulant type, population characteristics, years life lost (YLL). Design: Trend analysis age-adjusted rates using serial cross-section data 2023. Methods: Using National Vital Statistics System data, we analyzed (AAMRs) where was underlying cause death stimulants were contributing factors. We used Joinpoint regression estimate average annual percent change (AAPC) compare across groups. calculated YLL based on age at demographic-specific expectancies. Results: From rose sharply (AAPC: 10.1%), contrasting stable overall 0.2%). Methamphetamine-involved deaths faster 13.8%) than cocaine-involved 6.5%). Among cerebrovascular showed steepest rise 15.9%), followed by hypertensive (12.1%) ischemic heart diseases (7.9%). Older adults (⩾65 years) exhibited most pronounced increase 20.2%), while non-Hispanic American Indian/Alaska Native populations experienced highest AAPC among racial/ethnic groups (18.1%). Stimulant-involved caused nearly 1 million YLL, predominantly middle-aged males (687 430 YLL) White individuals (511 120 YLL). Methamphetamine involvement (580 570 exceeded that cocaine (423 528 Within types, leading (406 248 Conclusions: has surged, especially older adults, showing largest subtypes. The findings reveal importance targeted prevention, screening, intervention.

Language: Английский

Citations

0
Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial DOI Creative Commons
Nadine Ezard, Brendan Clifford, Krista J. Siefried

et al.

Addiction, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 19, 2024

Abstract Aims This study tested the efficacy and safety of a 12‐week course lisdexamfetamine in reducing methamphetamine use, an outcome which is associated with improvements health wellbeing, people dependent on methamphetamine. Design, setting participants was randomised double‐blind placebo‐controlled trial conducted six specialist outpatient clinics Adelaide, Melbourne, Newcastle Sydney, Australia (2018–2021). Participants were164 adults dependence, reporting at least 14 use days out previous 28 (62% male, 38% female, < 1% other; mean age 39 years). Interventions were randomly allocated 1:1 to 15‐week regimen (1‐week induction 250 mg, maintenance regimen, 2‐week reduction; n = 80) or matched placebo ( 84), followed‐up Week 19. Measurements The primary measure past 28‐day 13. Safety assessed by adverse event rates. Secondary measures included during treatment period satisfaction. Findings Nine randomized did not start (five four placebo) excluded from analyses. Fifty‐seven per cent retained medication end‐point. There only weak evidence benefit 13 weeks [adjusted difference 2.2, 95% confidence interval (CI) –0.5 5.0; P 0.49]. However, throughout whole phase, group had fewer total (difference 8.8, CI 2.7–15.0; 0.005). reported greater self‐reported effectiveness [odds ratio (OR) 2.89, 1.67–5.02; 0.001] satisfaction (OR 3.80, 1.93–7.47; 0.001). Adverse events nausea. Serious occurred (5%) who received lisdexamfetamine. Conclusions Lisdexamfetamine appears reduce over period, although there that reduced maintained last 4 weeks.

Language: Английский

Citations

3
Emerging medications and pharmacological treatment approaches for substance use disorders DOI Creative Commons
Joel S. Raymond, Anastasios Athanasopoulos, Connie J. Badolato

et al.

Pharmacology Biochemistry and Behavior, Journal Year: 2024, Volume and Issue: 248, P. 173952 - 173952

Published: Dec. 22, 2024

Language: Английский

Citations

1
IUPHAR Editorial: Emerging Targets for the Treatment of Pain: Moving towards non-addicting therapeutics and New Preclinical Directions DOI Creative Commons
James E. Barrett, Alvin V. Terry

Pharmacological Research, Journal Year: 2024, Volume and Issue: 209, P. 107339 - 107339

Published: Aug. 4, 2024

Language: Английский

Citations

0
Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study DOI
Heather E. Webber,

Jessica C. Badawi,

Douglas Calvillo

et al.

Journal of Addictive Diseases, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 8

Published: Dec. 28, 2024

Background: No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved insomnia treatment, reduces MA self-administration and MA-induced reinstatement responding in preclinical studies. SUVO may also reduce by targeting substance risk factors, including insomnia, stress, cue reactivity, craving. This case series study assessed the (1) feasibility safety of administering suvorexant sample individuals with MUD; (2) preliminary effects on objective subjective measures sleep, reactivity/craving. Method: Participants (n = 3) were randomized to receive 1 week or placebo using within-subject, crossover design 1-week washout period between doses. completed self-report (sleep quality, stress), behavioral (cold pressor task), physiological (heart rate, electroencephalogram) during all three weeks. wore Fitbit monitor sleep throughout study. Results: visits tasks. One report severe drowsiness headache made; no other side associated SUVO. improved total time resulted lower resting-state alpha power, but was mixed quality. administration increased overall brain reactivity cues not specific reduced though self-reported stress demonstrated results. Conclusion: safe tolerable MUD sample. Future research benefit from investigating well-controlled larger

Language: Английский

Citations

0